Literature DB >> 23571420

Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study.

Scott E Lukas1, Steven B Lowen, Kimberly P Lindsey, Nina Conn, Wendy Tartarini, John Rodolico, Gopi Mallya, Christopher Palmer, David M Penetar.   

Abstract

Oral naltrexone reduces heavy drinking, but is less consistent as an abstinence promoter, whereas once-monthly extended-release naltrexone (XR-NTX) also maintains abstinence. The present study sought to determine if alcohol cue reactivity is attenuated by XR-NTX. Twenty-eight detoxified alcohol-dependent adult male and female volunteers received a single i.m. injection of either XR-NTX or placebo under double-blind conditions. An fMRI/cue reactivity procedure was conducted immediately before and two weeks after injection. At baseline, alcohol-related visual and olfactory cues elicited significant increases in orbital and cingulate gyri, inferior frontal and middle frontal gyri. Subsequently, brain activation was significantly altered in XR-NTX-treated individuals. These affected brain regions are associated with the integration of emotion, cognition, reward, punishment, and learning/memory, suggesting that XR-NTX attenuates the salience of alcohol-related cues. Such an effect on brain function may interrupt the processes associated with "slips" and relapse, which may account for XR-NTX's ability to maintain abstinence.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23571420     DOI: 10.1016/j.neuroimage.2013.03.055

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  39 in total

1.  Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.

Authors:  Joseph P Schacht; Patrick K Randall; Patricia K Latham; Konstantin E Voronin; Sarah W Book; Hugh Myrick; Raymond F Anton
Journal:  Neuropsychopharmacology       Date:  2017-04-14       Impact factor: 7.853

Review 2.  Multisensory Environments to Measure Craving During Functional Magnetic Resonance Imaging.

Authors:  Kimberly Goodyear
Journal:  Alcohol Alcohol       Date:  2019-05-01       Impact factor: 2.826

Review 3.  Inhalation of Alcohol Vapor: Measurement and Implications.

Authors:  Robert Ross MacLean; Gerald W Valentine; Peter I Jatlow; Mehmet Sofuoglu
Journal:  Alcohol Clin Exp Res       Date:  2017-01-05       Impact factor: 3.455

4.  Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.

Authors:  Zhenhao Shi; An-Li Wang; Kanchana Jagannathan; Victoria P Fairchild; Charles P O'Brien; Anna Rose Childress; Daniel D Langleben
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

5.  Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.

Authors:  Robert Miranda; Stephanie S O'Malley; Hayley Treloar Padovano; Ran Wu; Daniel E Falk; Megan L Ryan; Joanne B Fertig; Thomas H Chun; Srinivas B Muvvala; Raye Z Litten
Journal:  Alcohol Clin Exp Res       Date:  2020-05-25       Impact factor: 3.455

6.  Development of stimulus material for research in alcohol use disorders.

Authors:  Werner Fey; Franz Moggi; Kristina B Rohde; Chantal Michel; Andrea Seitz; Maria Stein
Journal:  Int J Methods Psychiatr Res       Date:  2016-10-12       Impact factor: 4.035

7.  The fMRI BOLD response to unisensory and multisensory smoking cues in nicotine-dependent adults.

Authors:  Bernadette M Cortese; Thomas W Uhde; Kathleen T Brady; F Joseph McClernon; Qing X Yang; Heather R Collins; Todd LeMatty; Karen J Hartwell
Journal:  Psychiatry Res       Date:  2015-10-09       Impact factor: 3.222

8.  Neuroimaging in Alcohol and Drug Dependence.

Authors:  Mark J Niciu; Graeme F Mason
Journal:  Curr Behav Neurosci Rep       Date:  2014-03-01

9.  A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.

Authors:  Milky Kohno; Laura E Dennis; Holly McCready; Daniel L Schwartz; William F Hoffman; P Todd Korthuis
Journal:  Drug Alcohol Depend       Date:  2018-09-21       Impact factor: 4.492

Review 10.  Neuroimaging the Effectiveness of Substance Use Disorder Treatments.

Authors:  Elizabeth A Cabrera; Corinde E Wiers; Elsa Lindgren; Gregg Miller; Nora D Volkow; Gene-Jack Wang
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.